Of course. Consider the last offering was at $1.80 (just 4 cents below yesterdays closing). Since that time 5 institutions have added Millions of shares. We have a huge run on heavy volume just before the quarterly filings - up close to 20% in one day, and now a slow walkback towards the $1.80 mark. It's pretty obviously the stock is being manipulated so institutions can continue adding below 2. And over the past couple days we've had those intra-day panic runs towards $2, where investors are getting nervous that they've missed the last chance to buy. Just a matter of time before it breaks to the upside. Why do you think Broadfin and Baker Bros gobble up such huge positions they had to file 13D's in the middle of the quarter?
I agree, Baker holding IDRA is great, adding last quarter even sweeter, but the common tread of Baker, PCYC, IDRA and Lymphoma raised eyebrows. Something special about IDRA I bet. Trial kicks off soon.
Interesting that Baker Bros was one of the earliest and largest holders of Pharmacyclics, and now they appear to be doing the same with Idera. PCYC's superstar Imbruvica targets Mantle Cell Lymphoma, and Idera's lead candidate IMO-8400 targets Lymphoma as well. Perhaps, just perhaps, Baker Bros sees IDRA as the next PCYC. Looks like trial activity in this area for Idera will be spinning up shortly. Thoughts from other Idera longs?
Rather than let Surfaxin cut into their market share, could either Abbott or Forest, just consider buying DSCO? Otherwise, they risk having their animal derived surfactants (Survanta and Calfactant) sales decimated by Discovery's Surfaxin.
Hey I'm just pointing out the disappointing results. Don't blame me. The p-value at 12 months is not good. And I don't think the data supports the current price level.
Not much difference than standard stents at 12 months. 2% difference isn't statistically significant. How would the FDA ever approve something like this? Ugly open tomorrow.
Don't ignore the warning signs.